- Home
- KPLT vs VTVT Comparison
KPLT vs VTVT Comparison
Compare KPLT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- VTVT
- Stock Information
- Founded
- KPLT 2012
- VTVT 2015
- Country
- KPLT United States
- VTVT United States
- Employees
- KPLT N/A
- VTVT N/A
- Industry
- KPLT Diversified Commercial Services
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- VTVT Health Care
- Exchange
- KPLT Nasdaq
- VTVT Nasdaq
- Market Cap
- KPLT 52.2M
- VTVT 54.4M
- IPO Year
- KPLT N/A
- VTVT 2015
- Fundamental
- Price
- KPLT $11.39
- VTVT $21.75
- Analyst Decision
- KPLT Hold
- VTVT Strong Buy
- Analyst Count
- KPLT 1
- VTVT 2
- Target Price
- KPLT $10.00
- VTVT $35.50
- AVG Volume (30 Days)
- KPLT 65.8K
- VTVT 4.5K
- Earning Date
- KPLT 11-12-2025
- VTVT 11-12-2025
- Dividend Yield
- KPLT N/A
- VTVT N/A
- EPS Growth
- KPLT N/A
- VTVT N/A
- EPS
- KPLT N/A
- VTVT N/A
- Revenue
- KPLT $267,101,999.00
- VTVT $17,000.00
- Revenue This Year
- KPLT $22.88
- VTVT N/A
- Revenue Next Year
- KPLT $10.98
- VTVT N/A
- P/E Ratio
- KPLT N/A
- VTVT N/A
- Revenue Growth
- KPLT 13.04
- VTVT N/A
- 52 Week Low
- KPLT $5.08
- VTVT $12.62
- 52 Week High
- KPLT $24.34
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- KPLT 39.32
- VTVT 55.00
- Support Level
- KPLT $11.91
- VTVT $19.80
- Resistance Level
- KPLT $12.94
- VTVT $21.99
- Average True Range (ATR)
- KPLT 0.98
- VTVT 1.11
- MACD
- KPLT 0.04
- VTVT -0.17
- Stochastic Oscillator
- KPLT 22.47
- VTVT 60.00
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.